MARKET

ABEO

ABEO

Abeona
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.510
-0.030
-1.95%
After Hours: 1.520 +0.01 +0.66% 19:15 12/04 EST
OPEN
1.550
PREV CLOSE
1.540
HIGH
1.567
LOW
1.490
VOLUME
1.24M
TURNOVER
--
52 WEEK HIGH
5.19
52 WEEK LOW
0.9895
MARKET CAP
148.78M
P/E (TTM)
-1.4563
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Verastem (VSTM) Begins Phase II Combo Study for Ovarian Cancer
Verastem (VSTM) initiates phase II registration-directed study of VS-6766 and defactinib in patients with recurrent low-grade serous ovarian cancer.
Zacks · 4d ago
Is the Options Market Predicting a Spike in Abeona (ABEO) Stock?
Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.
Zacks · 4d ago
HorizonTherapeutics (HZNP) Rises YTD on Approvals & Buyouts
Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza in 2021. It is making efforts to expand the label for its marketed drugs.
Zacks · 11/27 13:25
Eiger (EIGR) Gets FDA Approval for Zokinvyin Rare Diseases
Eiger (EIGR) gets FDA approval for Zokinvy for the treatment of Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies.
Zacks · 11/24 20:10
Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology
Horizon (HZNP) inks deal to get an exclusive access to Halozyme's ENHANZE drug delivery technology for subcutaneous formulation of medicines targeting IGF-1R.
Zacks · 11/24 20:08
Amgen (AMGN) Ends Deal With Cytokinetics for Heart Candidate
Amgen (AMGN) will terminate the collaboration with Cytokinetics and transition development and commercialization rights for omecamtiv mecarbil and AMG 594 to the latter.
Zacks · 11/24 20:07
Novo Nordisk's (NVO) Phase IIIb Study Meets Primary Endpoint
Novo Nordisk's (NVO) semaglutide 2.0 mg demonstrates superior reduction in HbA1c versus once-weekly semaglutide 1.0 mg in people with type II diabetes.
Zacks · 11/18 16:24
Kodiak (KOD) Closes Enrollment in Phase IIb/III Wet AMD Study
Zacks · 11/17 18:16
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ABEO. Analyze the recent business situations of Abeona through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ABEO stock price target is 5.40 with a high estimate of 8.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 151
Institutional Holdings: 42.43M
% Owned: 43.06%
Shares Outstanding: 98.53M
TypeInstitutionsShares
Increased
19
646.53K
New
25
-2.42M
Decreased
32
5.78M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chief Financial Officer/Chief Accounting Officer/Vice President
Edward Carr
Chief Operating Officer
Michael Amoroso
Director
Christine Silverstein
Chief Financial Officer/IR Contact Officer
Christine Berni-Silverstein
Independent Director
Paul Mann
Independent Director
Todd Wider
Other
Max Colao
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ABEO
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Abeona Therapeutics Inc stock information, including NASDAQ:ABEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABEO stock methods without spending real money on the virtual paper trading platform.